TRI selected to present on RBM at 51st Annual DIA

Driven by high levels of industry interest in risk-based monitoring (RBM), the DIA are using the CDM and Technology symposium at this year's event in Washington to focus entirely on RBM based topics. The symposium will include presentations from three guest speakers. We are delighted to announce that Tammy Finnigan, TRI’s COO has been selected as one of those three, and will be presenting the key findings from one of our ongoing RBM pilot studies being conducted using TRI's RBM platform, OPRA.

The title of Tammy’s presentation will be  “Therapeutic Area Key Risk Indicators:  Digestive Disease”. The content in the presentation will be based on the experience gained from one of our RBM pilots being run using TRI’s RBM platform, OPRA. The presentation aims to take the audience through the journey of the project team, outlining the objectives of the project, the approach taken to risk identification, the data identified for investigation and the reasons why. The presentation will summarize the analysis performed and the results achieved. The presentation will close by presenting the data which has been identified as surrogate markers for site quality and further information on how these are being applied as risk indicators to digestive disease clinical programs which are following a risk-based approach to monitoring.

The DIA’s 51st Annual meeting will take place on June 14-18 at the Walter E. Washington Convention Center, 801 Mount Vernon Place NW, Washington, DC 20001.For further information on the event, please follow the link below:

We will be offering private meetings and demos of our RBM solution, OPRA, at the event, so contact for more details.

We look forward to seeing you there!